Article

Motor signs during the course of Alzheimer disease. [Electronic version]

Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, and Department of Neurology, New York, NY 10032, USA.
Neurology (Impact Factor: 8.29). 10/2004; 63(6):975-82. DOI: 10.1212/01.WNL.0000138440.39918.0C
Source: PubMed

ABSTRACT

Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care.
To describe the progression and identify predictors of individual MOSIs in AD.
A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years (mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the Unified Parkinson's Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were performed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified.
At least one MOSI was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%), posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to 6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at last evaluation) and worsened less (0.75% increase/year).
Most motor signs occur frequently and progress rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.

Download full-text

Full-text

Available from: Jason Brandt, Jan 08, 2014
  • Source
    • "Clinical presentation of Alzheimer's disease (AD) is complex and extends well beyond the cognitive impairments that characterize this disorder (Duker et al., 2012). Alterations in facial expression, gait and posture, and manifestations of rigidity, bradykinesia, and tremor are found in late AD stages although mounting evidence suggests that motor problems emerge long before any recognizable sign of AD (Wilson et al., 2000; Scarmeas et al., 2004; Buchman & Bennett, 2011 ). Tau abnormal hyperphosphorylation and subsequent malfunction are postulated as crucial mechanisms in AD neuronal dysfunction where hyperphosphorylated and/or aggregated (insoluble) forms of Tau exhibit neurodegenerative action(s) that also interfere with normal Tau, sequestering and reducing soluble Tau forms (Ksiezak-Reding et al., 1988; Zhukareva et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dementia is the cardinal feature of Alzheimer's disease (AD), yet the clinical symptoms of this disorder also include a marked loss of motor function. Tau abnormal hyperphosphorylation and malfunction are well-established key events in AD neuropathology but the impact of the loss of normal Tau function in neuronal degeneration and subsequent behavioral deficits is still debated. While Tau reduction has been increasingly suggested as therapeutic strategy against neurodegeneration, particularly in AD, there is controversial evidence about whether loss of Tau progressively impacts on motor function arguing about damage of CNS motor components. Using a variety of motor-related tests, we herein provide evidence of an age-dependent motor impairment in Tau-/- animals that is accompanied by ultrastructural and functional impairments of the efferent fibers that convey motor-related information. Specifically, we show that the sciatic nerve of old (17-22-months) Tau-/- mice displays increased degenerating myelinated fibers and diminished conduction properties, as compared to age-matched wild-type (Tau+/+) littermates and younger (4-6 months) Tau-/- and Tau+/+ mice. In addition, the sciatic nerves of Tau-/- mice exhibit a progressive hypomyelination (assessed by g-ratio) specifically affecting large-diameter, motor-related axons in old animals. These findings suggest that loss of Tau protein may progressively impact on peripheral motor system.
    Full-text · Article · Jan 2016 · Aging Cell
  • Source
    • "The earliest symptoms are abnormal amnesia and a decline of attentional control of executive functions (Perry and Hodges, 1999; Sperling et al., 2011; Simon et al., 2012). Interestingly, several authors highlighted the onset and gradual increase in motor impairments throughout the course of the illness (Scarmeas et al., 2004; Buchman and Bennett, 2011). These motor alterations in MCI and AD patients mainly concern certain features of gait and balance function, and lead to an increased risk of falling (Van Iersel et al., 2004; Camicioli et al., 2006) they also impair the realization of fine movements (Yan et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This internal representation of movement of part(s) of the body is involved during Implicit Motor Imagery tasks (IMI); the same representations are employed in the laterality judgment task. Few studies have looked at the consequences of aging, Alzheimer's disease (AD) and mild cognitive impairment (MCI) on the processes of motor preparation but none showed evidence of an alteration of action representation in patient with amnestic MCI. In the present study, the IMI task was used to assess the action representation abilities in MCI patients and healthy counterparts. A total of 24 elderly participants aged between 65 and 90 years old (12 women, 73.4 ± 6 years, mean ± S.D.) were recruited: 12 patients with MCI (MCI group) and 12 healthy aged adults (HAA group). The results showed that MCI patients have significantly a greater response time (RT) than HAA subjects only in IMI task and more precisely when performing their mental rotation at the challenging conditions. Furthermore, the IMI task related to the non-dominant hand induced a significant increase of RT only in MCI subjects. At the light of these results, we assume that MCI patients are able to engage themselves in IMI processes, still showing a compelling impairment of this mental ability across its complexity.
    Full-text · Article · Dec 2015 · Frontiers in Aging Neuroscience
    • "In comparison to the vast literature on cognitive decline during the course of AD, detailed reports on the impact of motor symptoms in AD patients are scarce [47] [48]. Motor dysfunction has been reported in later disease stages [48] [49], but there is accumulating evidence that they are also present in mildly demented AD patients [50], that they might be a characteristic feature of early AD pathology [51] and that they even might bear some predictive value [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: According to the modified amyloid hypothesis, the key event in the pathogenesis of Alzheimer's disease (AD) is the deposition of neurotoxic amyloid β-peptides (Aβs) in plaques and cerebral blood vessels. Additionally to full-length peptides, a great diversity of N-truncated Aβ variants is derived from the larger amyloid-β protein precursor (AβPP). Vast evidence suggests that Aβ x-42 isoforms play an important role in triggering neurodegeneration due to their high abundance, amyloidogenic propensity and toxicity. Although N-truncated Aβ peptides and Aβ x-42 species appear to be the crucial players in AD etiology, the Aβ 2-x isoforms did not receive much attention yet. The present study is the first to show immunohistochemical evidence of Aβ 2-x in cases of AD and its distribution in AβPP/PS1KI and 5XFAD transgenic mouse models using a novel antibody pAB77 that has been developed using Aβ 2-14 as antigen. Positive plaques and congophilic amyloid angiopathy (CAA) were observed in AD cases and in both mouse models. While in AD cases, abundant CAA and less pronounced plaque pathology was evident, the two mouse models showed predominantly extracellular Aβ deposits and minor CAA staining. Western blotting and a capillary isoelectric focusing immunoassay demonstrated the high specificity of the antibody pAb77 against Aβ-variants starting with the N-terminal Alanine-2.
    No preview · Article · Oct 2015 · Journal of Alzheimer's disease: JAD
Show more